slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 216,631-216,660
Pages 10,126
Rows per page 30
Component
216,631-216,660 of 303,780
16
Includes reconciliation for EBITDA, Adjusted EBITDA, Adjusted Gross Profit, and Net Cash used in operations.Nano Dimension | Results Presentation Deck | 18 slides · Nano Dimension
Conference presentation Investor relations Beat · Conclusion1 hit
18
Includes footnotes regarding IFRS reconciliation and specific line item definitions.Nano Dimension | Results Presentation Deck | 18 slides · Nano Dimension
Conference presentation Investor relations Beat · Conclusion1 hit
01
Features a 3D rendering of a synapse.NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
02
NeuroSense Therapeutics | Investor Presentation Deck | 34 slidesNeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
03
The slide uses a standard drug development pipeline visualization.NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
05
The slide uses a list of key benefits to summarize the product's market and clinical position.NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
06
Includes a navigation bar at the bottom indicating the current section is 'PrimeC'.NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
08
The slide uses a bar chart to compare hazard ratios of multiple compounds against a vehicle control, with statistical significance markers.NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
09
Uses a chain-link visual metaphor to represent the combination of two distinct therapeutic strategies.NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
10
Includes a line chart showing PK data and a biological diagram illustrating the mechanism of action (blocking MDR-mediated efflux).NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
12
The slide uses a biological process diagram to illustrate how PrimeC modulates microRNA regulation, TDP-43 aggregation, and cellular recycling.NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
13
Includes a bar chart of motor performance and visual evidence of motor neuron recovery.NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
14
Includes a progress bar at the bottom indicating the current section is 'Phase 2a Results'.NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
15
The slide uses a comparative clinical trial analysis against a historical control database (PRO-ACT).NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
16
Includes a process diagram showing exosome extraction from blood samples.NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
17
Data shows p-values of 0.005 and <0.001 for treated groups, indicating significant biomarker reduction.NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
18
The slide uses a process-flow diagram to link trial results to the next phase of development.NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
21
The slide uses a logo-grid layout to establish credibility through institutional and industry partnerships.NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
22
The slide uses a color-coded legend for ALS, Alzheimer's, and Parkinson's.NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
23
NeuroSense Therapeutics | Investor Presentation Deck | 34 slidesNeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
24
NeuroSense Therapeutics | Investor Presentation Deck | 34 slidesNeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
25
The slide includes a progress bar at the bottom indicating the current section is 'Summary'.NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
27
Includes stock price, market cap, cash position, and analyst coverage.NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
28
Includes a team photo and a progress bar at the bottom indicating the current slide is the 'Summary' section.NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
29
NeuroSense Therapeutics | Investor Presentation Deck | 34 slidesNeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
31
The chart shows a negative correlation trend line between TDP-43 change and ALSFRS-R slope.NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
32
NeuroSense Therapeutics | Investor Presentation Deck | 34 slidesNeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
34
Includes a navigation bar at the bottom indicating the current section is 'Phase 2b'.NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
01
Includes a footnote indicating the company was formerly known as Nexters.Nexters | Investor Presentation Deck | 19 slides · GDEV
Pitch deck Investor relations 1 hit
02
Nexters | Investor Presentation Deck | 19 slidesNexters | Investor Presentation Deck | 19 slides · GDEV
Pitch deck Investor relations 1 hit